Ligand Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Ligand Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Ligand Pharmaceuticals: 15 sponsored US clinical trials, none currently recruiting.
Ligand Pharmaceuticals sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 15 completed. 2 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sarcoma, Kaposi, with 1 trials.
Top-decile sponsor footprint
Ligand Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
15 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
15 total, page 1 of 1
A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus
NCT02851849
A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation
NCT02672839
Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus
NCT02250222
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
NCT01919684
A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension
NCT00635232
The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome
NCT00626418
The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease
NCT00623324
A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension
NCT00522925
Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus
NCT00458016
Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma
NCT00073736
Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss
NCT00163137
Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)
NCT00141323
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
NCT00006345
Bexarotene in Treating Patients With Metastatic Breast Cancer
NCT00003752
A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma
NCT00002212
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 9 |
| Phase 3 | 2 |
Therapeutic Areas
How the Ligand Pharmaceuticals early-phase archive is shaped
15 indexed studies, none listed as recruiting (0% open); 15 completed (100%).
Phase mix: 2 late (III/IV) vs 13 early (I/II) (early-phase heavy).
Top condition: Sarcoma, Kaposi (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Ligand Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Ligand Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 archived trials
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Ligand Pharmaceuticals page
15 registered trials is a research-attention snapshot, not an endorsement of Ligand Pharmaceuticals or any single study.
- None of Ligand Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Sarcoma, Kaposi is the condition Ligand Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sarcoma, Kaposi trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ligand Pharmaceuticals pipeline card: 15 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.